Replimune Group (NASDAQ:REPL) Shares Gap Up – Time to Buy?

Replimune Group, Inc. (NASDAQ:REPL)’s share price gapped up before the market opened on Monday . The stock had previously closed at $12.49, but opened at $12.97. Replimune Group shares last traded at $12.44, with a volume of 74,714 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on REPL. Jefferies Financial Group increased their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. BMO Capital Markets increased their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a report on Friday, November 22nd. JPMorgan Chase & Co. lifted their target price on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Replimune Group in a research note on Friday, November 22nd. Finally, Roth Mkm assumed coverage on Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price on the stock. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $17.29.

Replimune Group Trading Down 0.6 %

The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The company has a market capitalization of $849.74 million, a PE ratio of -4.07 and a beta of 1.26. The company’s fifty day moving average is $12.25 and its 200-day moving average is $10.77.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. On average, analysts anticipate that Replimune Group, Inc. will post -2.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC boosted its stake in Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares during the period. Point72 DIFC Ltd purchased a new stake in Replimune Group in the second quarter valued at approximately $57,000. Arizona State Retirement System purchased a new stake in shares of Replimune Group in the 2nd quarter valued at $108,000. Quest Partners LLC grew its position in Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after acquiring an additional 3,150 shares in the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in shares of Replimune Group during the third quarter worth about $133,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.